Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 3/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491133 | 0.88 | ADRA2C (0.42) | ADRA2AADRA1DADRA1AADRA1BADRA2C | |
| SCHEMBL6488223 | 0.88 | MAPT (0.42) | ADRA2AADRA1DADRA1AADRA1BADRA2C | |
| SCHEMBL6489663 | 0.88 | MAP3K14 (0.41) | CDK5CDK5R1ADRA2AADRA1DADRA1A | |
| SCHEMBL6486887 | 0.86 | MAPT (0.41) | ADRA2AADRA1DADRA1AADRA1BADRA2C | |
| SCHEMBL6488243 | 0.82 | CDK5 (0.43) | CDK5CDK5R1ADRA2AADRA1AADRA2C | |
| SCHEMBL6488248 | 0.82 | CDK5 (0.43) | CDK5CDK5R1ADRA2AADRA1AADRA2C | |
| SCHEMBL6488762 | 0.82 | ADRA2C (0.40) | CDK5CDK5R1ADRA2AADRA1DADRA1A | |
| SCHEMBL6500360 | 0.81 | MAOA (0.37) | CDK5CDK5R1ADRA2AADRA1DADRA1A | |
| SCHEMBL6496901 | 0.76 | HTR2A (0.37) | CDK5CDK5R1PIKFYVENISCHKDR | |
| SCHEMBL6496897 | 0.76 | HTR2A (0.37) | CDK5CDK5R1PIKFYVENISCHKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951881-B2 | (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | CDK5 316/4885CDK5R1 257/4885ADRA2A 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.